当前位置:首页>产品中心>抗原/重组蛋白>Recombinant Human GLA (C-6His)

Recombinant Human GLA (C-6His)

  • 货号:EPT291
  • 价格:¥26,400.00 元
  • 点击:171

产品介绍

基本信息

规格1mg
表达宿主Human Cells
标签C-6His

物理性质

分子量46.39 KDa
表观分子量50-60 KDa, reducing conditions
形态Supplied as a 0.2 μm filtered solution of 20mM Tris-HCl, 150mM NaCl, pH 8.0.
纯度Greater than 95% as determined by reducing SDS-PAGE.

活性与内毒素

内毒素水平Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
活性Measured by its ability to hydrolyze 4-Nitrophenyl -alpha -D-galactopyranoside. The specific activity is 2835 pmol/min/µg.

储存与运输

储存方法Store at ≤-70°C, stable for 6 months after receipt.
Store at ≤-70°C, stable for 3 months under sterile conditions after opening.
Please minimize freeze-thaw cycles.
运输条件The product is shipped on dry ice/polar packs.
Upon receipt, store it immediately at the temperature listed below.

详细说明

背景说明α-Galactosidase A is a homodimeric glycoprotein that belongs to the glycosyl hydrolase 27 family. It is a lysosomal enzyme and used as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease. α-Galactosidase A can hydrolyze terminal α-galactosyl moieties from glycolipids and glycoproteins and catalyze the hydrolysis of melibiose into galactose and glucose. Defects α-Galactosidase A are the cause of Fabry disease (FD) which is a rare X-linked sphingolipidosis disease with glycolipid accumulates in many tissues. The disease consists of an inborn error of glycosphingolipid catabolism. FD patients show systemic accumulation of globotriaoslyceramide (Gb3) and related glycosphingolipids in the plasma and cellular lysosomes throughout the body. Patients may show ocular deposits, febrile episodes, and burning pain in the extremities. Death results from renal failure, cardiac or cerebral complications of hypertension or other vascular disease.
【仅供科学研究使用】

相关产品:
总计 800 个记录,共 40 页,当前第 3 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00